Xiromed, LLC’s Post

The relationship between pharmaceutical sales representatives and physicians has long been a topic of debate. Recent studies have shed light on an intriguing phenomenon: the prescribing of generic drugs tends to increase when sales visits from pharmaceutical representatives decrease. This article delves into the intricate dynamics of this relationship, exploring its implications for healthcare providers, patients, and the pharmaceutical industry as a whole. https://lnkd.in/eRzZQQHH

Curious about the latest EU pharmaceutical reforms?🩺💊 Our latest article by Phillipus Putter explores the European Commission’s proposed reforms for the regulation of paediatric medicinal products. Since our initial coverage in July 2023 and following the Parliament’s first reading in April 2024, several key changes have been introduced. This update is crucial for stakeholders in the pharmaceutical industry, especially those focused on paediatric medicines. To understand the full impact of these changes and stay ahead in the industry, read the full article here: https://2bird.ly/48sef8C

Expert Discusses the Impact of Medicare Drug Pricing Reforms on the Pharmaceutical Industry - Pharmacy Times: Expert Discusses the Impact of Medicare Drug Pricing Reforms on the Pharmaceutical Industry  Pharmacy Times

Expert Discusses the Impact of Medicare Drug Pricing Reforms on the Pharmaceutical Industry - Pharmacy Times: Expert Discusses the Impact of Medicare Drug Pricing Reforms on the Pharmaceutical Industry  Pharmacy Times

Pharmaceutical Drug Delivery Market to Hit USD 2,546 Billion by 2029 | MarketsandMarkets™ https://lnkd.in/g4-FE7jB DELRAY BEACH, Fla., Sept. 17, 2024 /PRNewswire/ — The global pharmaceutical drug delivery market is set to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029, with a CAGR of 5.5%. [...]

To my international network: Do you have a national pharmaceutical strategy in your country? Let me know in the comments! In Sweden, the first national pharmaceutical strategy was released in 2011 and has been revised three times. The current strategy, that the Swedish government has released, is valid between 2024-2026 and covers three focus areas: - availability of new and old medicines - pharmaceutical treatment and medicine handling - development of new medicines and clinical trials

The relationship between pharmaceutical sales representatives and physicians has long been a topic of debate. Recent studies have shed light on an intriguing phenomenon: the prescribing of generic drugs tends to increase when sales visits from pharmaceutical representatives decrease. This article delves into the intricate dynamics of this relationship, exploring its implications for healthcare providers, patients, and the pharmaceutical industry as a whole. https://lnkd.in/ehZYEgUY

The pricing of generic drugs is a crucial aspect of the pharmaceutical industry, with significant implications for consumers and healthcare systems worldwide. In this article, we will delve into the various strategies employed by pharmaceutical companies to set the prices of their generic medicines, highlighting the key factors that influence these decisions and the impact they have on the market. https://lnkd.in/eCA4rn-T

📢 #DrugPatentWatch: This Week's Expiration Report At Unibest, we're committed to keeping our partners informed about upcoming opportunities in the pharmaceutical industry. Our weekly patent expiration watch helps you stay ahead of the curve. This week, we're monitoring these significant drugs approaching patent and exclusivity milestones: 💊 ABRAXANE by Bristol Myers Squibb; containing Paclitaxel 💊 TRIKAFTA by Vertex Pharmaceuticals; containing Elexacaftor, Ivacaftor, and Tezacaftor 💊 XIPERE by Bausch + Lomb; containing Triamcinolone Acetonide As these drugs approach patent expiration, new opportunities arise for generic development and market entry. At Unibest, we're poised to support pharmaceutical companies in navigating these opportunities with our comprehensive R&D, CDMO, and manufacturing services. For a more detailed analysis and to explore how these changes might impact your business, visit our blog: https://lnkd.in/gtqDs7Ex #Pharmaceuticals #GenericDrugs #DrugDevelopment #CDMO #Unibest

Six “Antimicrobial Resistance (AMR) Roadmaps”, one for each of the World Health Organization regions, that define and prioritise major milestones towards mitigating AMR for the period 2024 to 2028, are published by FIP today. The roadmaps were developed by FIP in collaboration with its regional pharmaceutical forums and, for the European Region, with FIP member organisations in Europe as there is no FIP regional pharmaceutical forum in the European region. The new roadmaps have been developed to follow roadmaps for 2020-2024. The new publication also presents various activities against AMR that have been undertaken in countries of each region. Access the roadmaps here www.fip.org/file/6112